Business Context and Reporting Period
This Form 8-K was filed by Genprex, Inc. on May 23, 2018. The report discloses the execution of an Amended and Restated Employment Agreement with Julien L. Pham, MD, MPH, the company's President and Chief Operating Officer. The filing updates the terms of Dr. Pham's employment originally established in October 2016.
Key Financial Metrics
The filing does not provide general financial statements, revenue, profit, cash flow, or debt metrics for the company. The only specific financial figures disclosed relate to executive compensation:
- Base Salary: $325,000 annually.
- Target Bonus (2018): Up to 33.33% of base salary.
- Equity Grant: Options to purchase 659,346 shares at an exercise price of $9.80 per share.
- Severance Conditions: Certain severance payments are contingent on the company maintaining at least $5 million in cash/cash equivalents and a net worth of at least $5 million at the time of termination.
Material Changes
The primary material change is the amendment of Dr. Pham's employment terms, specifically:
- Formalization of a $325,000 base salary and a performance-based bonus structure.
- Grant of new stock options split between time-based vesting (50%) and performance-based vesting (50%).
- Definition of specific severance packages triggered by termination without cause or resignation for good reason, both pre- and post-change of control.
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Employment Status: Employment is "at-will" and terminable by either party at any time.
- Severance Contingency: The company's obligation to pay severance (12 months' salary and target bonus) is conditional on the company's financial health (minimum $5 million cash and net worth). If these thresholds are not met, these specific payments may not be triggered.
- Non-Compete: Dr. Pham is restricted from competing with Genprex or soliciting employees for one year post-employment.
- Definitions of Cause and Good Reason: The agreement strictly defines "cause" (e.g., gross negligence, fraud, felony conviction) and "good reason" (e.g., material reduction in duties or salary, relocation >50 miles) which dictate eligibility for severance.
Investor Verification Checklist
- Verify the company's current cash position and net worth to assess the likelihood of triggering the $5 million severance conditions.
- Review the specific performance goals attached to the 50% of stock options designated as performance-based.
- Confirm the vesting schedule for the time-based options (1/3 on May 23, 2019; remainder quarterly over two years).
- Examine the full text of Exhibit 10.1 for any additional covenants or restrictions not summarized in the 8-K.